Whitepaper: Indication based pricing – Widely advocated but not yet feasible
Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications.
In this whitepaper we explore:
- The concept of value and IBP in medicines pricing
- Key medicines which have attempted an IBP style strategy
- Observations of IBP in Germany and France
- Challenges facing the adoption of IBP
Simply fill in the form below and we’ll send you a copy of the whitepaper.